April 2026
Ayahuasca
What April 2026's 8 new studies found, synthesized from the papers below. All Ayahuasca research →
The synthesis
Synthesized from 6 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Ayahuasca, yage, hoasca, banisteriopsis, then ranked by relevance.
Research published in April 2026 indicates that ayahuasca shows promise for reducing depressive symptoms and suicidal ideation, with rapid effects reported in systematic reviews and sustained improvements in quality of life and personality in a large longitudinal study. However, evidence is limited by small sample sizes, methodological heterogeneity, and a lack of large-scale controlled trials, and legal and regulatory inconsistencies remain a significant concern.
Evidence by study
Direction is which way each study's own result points, not our rating of the study. All 8 matching studies were reviewed; the 6 that directly address the question are shown here.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| El estatuto legal internacional de la ayahuasca: una aproximación jurídica y antropológica 2026 | legal and policy analysis | Unclear | Argues that the expansion of ayahuasca use creates legal challenges and inconsistencies across states, highlighting the need for a new international regulatory framework. | |
| Ayahuasca Therapy: Possible Reduction of Suicidal Ideation in Treatment-Resistant Depression - A Systematic Review. 2026 | systematic review | 5 | Supports | Ayahuasca administration is associated with rapid and significant reductions in suicidal ideation and depressive symptoms in patients with depressive disorders. |
| Symmetrical Global Mental Health (Sym-GMH): Ayahuasca and shipibo traditional medicine for lasting changes in personality and quality of life 2026 | prospective longitudinal study | 264 | Supports | Shipibo-led ayahuasca retreats led to lasting improvements in personality, quality of life, and decentering capacities with minimal adverse effects. |
| Single exposure to Ayahuasca reverses chronic stress effects on sociability, anxiety, cortisol, and BDNF in zebrafish 2026 | experimental study | Supports | A single exposure to ayahuasca restored chronic stress-induced impairments in sociability, anxiety-like behavior, cortisol levels, and brain-derived neurotrophic factor in zebrafish. | |
| Responsible Ceremonial Medicine: A Review of Current Evidence, Safety Protocols, and Ethical Considerations for Professional Practice 2026 | review | Supports | Reviews evidence that psilocybin and ayahuasca show clinical efficacy for major depression and treatment-resistant depression, with neuroplasticity mechanisms and a three-phase model as the professional standard. | |
| POTENCIAL TERAPÊUTICO DA HOASCA NO TRATAMENTO DA DEPRESSÃO: REVISÃO DE ESCOPO 2026 | scoping review | 12 | Supports | Hoasca (ayahuasca) shows rapid and sustained antidepressant effects, with clinical improvements observed within 24 hours and lasting up to 21 days. |
Argues that the expansion of ayahuasca use creates legal challenges and inconsistencies across states, highlighting the need for a new international regulatory framework.
legal and policy analysis
Ayahuasca administration is associated with rapid and significant reductions in suicidal ideation and depressive symptoms in patients with depressive disorders.
systematic review Sample size: 5
Shipibo-led ayahuasca retreats led to lasting improvements in personality, quality of life, and decentering capacities with minimal adverse effects.
prospective longitudinal study Sample size: 264
A single exposure to ayahuasca restored chronic stress-induced impairments in sociability, anxiety-like behavior, cortisol levels, and brain-derived neurotrophic factor in zebrafish.
experimental study
Reviews evidence that psilocybin and ayahuasca show clinical efficacy for major depression and treatment-resistant depression, with neuroplasticity mechanisms and a three-phase model as the professional standard.
review
Hoasca (ayahuasca) shows rapid and sustained antidepressant effects, with clinical improvements observed within 24 hours and lasting up to 21 days.
scoping review Sample size: 12
Points of agreement
- Ayahuasca is associated with rapid reductions in depressive symptoms and suicidal ideation.
- Therapeutic effects are linked to neuroplasticity mechanisms, including BDNF upregulation.
- Ayahuasca shows potential for improving quality of life and personality with minimal adverse effects.
Conflicts
- No direct contradictions reported; however, the legal analysis highlights inconsistencies in regulatory frameworks, which may conflict with the therapeutic endorsement seen in clinical reviews.
Gaps
- Durability of effects beyond 12 months is not established.
- Most clinical evidence comes from small, heterogeneous studies; large-scale RCTs are lacking.
- Long-term safety and adverse effects in diverse populations are not fully characterized.
- Legal and regulatory frameworks for ayahuasca use remain inconsistent and unresolved.